Carregant...
Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
PURPOSE: Two chimeric antigen receptor T-cell (CAR-T) therapies have been approved in the United States (USA) in 2017 and Europe (EU) in 2018: axicabtagene ciloleucel and tisagenlecleucel. They contain the patient’s own T cells, which are extracted, genetically modified, and reinfused. Alongside the...
Guardat en:
| Publicat a: | Eur J Clin Pharmacol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Berlin Heidelberg
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8275491/ https://ncbi.nlm.nih.gov/pubmed/33608749 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00228-021-03106-z |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|